Skip to content

Net Income at other companies

Biogen logo
BiogenBIIB
$319.5M+32.8%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$49.01M-20.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.81M-100%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$120.85M-4.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$63.73M+12.3%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$97.35M-35.2%

Segments

By segment

See full
Single Reportable-$105.51M-41.2%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's net income?
Scholar Rock (SRRK) reported net income of -$105.51M in Q1 2026.
How has Scholar Rock's net income changed year-over-year?
Scholar Rock's net income decreased by 41.2% year-over-year, from -$74.72M to -$105.51M.
What is the long-term trend for Scholar Rock's net income?
Over 4 years (2021 to 2025), Scholar Rock's net income has grown at a 30.1% compound annual growth rate (CAGR), from -$131.8M to -$377.94M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.